JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB156324

Recombinant Human U2AF35/U2AF1 protein (denatured) (His tag N-Terminus)

Be the first to review this product! Submit a review

|

(0 Publication)

Recombinant Human U2AF35/U2AF1 protein (denatured) (His tag N-Terminus) is a Human Full Length protein, in the 1 to 240 aa range, expressed in Escherichia coli, with >90%, suitable for SDS-PAGE.

View Alternative Names

U2AF35, U2AFBP, FP793, U2AF1, Splicing factor U2AF 35 kDa subunit, U2 auxiliary factor 35 kDa subunit, U2 small nuclear RNA auxiliary factor 1, U2 snRNP auxiliary factor small subunit

1 Images
SDS-PAGE - Recombinant Human U2AF35/U2AF1 protein (denatured) (His tag N-Terminus) (AB156324)
  • SDS-PAGE

Unknown

SDS-PAGE - Recombinant Human U2AF35/U2AF1 protein (denatured) (His tag N-Terminus) (AB156324)

15% SDS-PAGE analysis of ab156324 (3μg).

Key facts

Purity

>90% SDS-PAGE

Expression system

Escherichia coli

Tags

His tag N-Terminus

Applications

SDS-PAGE

applications

Biologically active

No

Accession

Q01081

Animal free

No

Carrier free

No

Species

Human

Storage buffer

pH: 8 Constituents: 10% Glycerol (glycerin, glycerine), 2.4% Urea, 0.32% Tris HCl

storage-buffer

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "SDS-PAGE": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }

Product details

This product was previously labelled as U2AF35

Sequence info

[{"sequence":"MGSSHHHHHHSSGLVPRGSHMGSMAEYLASIFGTEKDKVNCSFYFKIGACRHGDRCSRLHNKPTFSQTILIQNIYRNPQNSAQTADGSHCAVSDVEMQEHYDEFFEEVFTEMEEKYGEVEEMNVCDNLGDHLVGNVYVKFRREEDAEKAVIDLNNRWFNGQPIHAELSPVTDFREACCRQYEMGECTRGGFCNFMHLKPISRELRRELYGRRRKKHRSRSRSRERRSRSRDRGRGGGGGGGGGGGGRERDRRRSRDRERSGRF","proteinLength":"Full Length","predictedMolecularWeight":"30.3 kDa","actualMolecularWeight":null,"aminoAcidEnd":240,"aminoAcidStart":1,"nature":"Recombinant","expressionSystem":"Escherichia coli","accessionNumber":"Q01081","tags":[{"tag":"His","terminus":"N-Terminus"}]}]

Properties and storage information

Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle
False

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

U2AF35 also known as U2AF1 is a protein weighing approximately 35 kDa. It interacts importantly in the pre-mRNA splicing process where it binds to the 3' splice site of introns. The protein is a subunit of the U2 auxiliary factor and its expression occurs across various tissues with particular concentrations in the developmental stages of tissues and in dynamic cellular environments. U2AF35 functions by recognizing the AG dinucleotide at the 3' end of introns a task critical for the accurate splicing of precursor mRNA.
Biological function summary

This protein plays an important role in the removal of introns from pre-mRNA impacting the processing of mRNA which ultimately affects gene expression. U2AF35 is a component of the spliceosome complex particularly influencing the recruitment of U2 small nuclear ribonucleoprotein (snRNP) to the branch point. The activity of U2AF35 ensures proper mRNA maturation which is essential in controlling the flow of genetic information from DNA to protein synthesis. It also contributes to the alternative splicing allowing cells to produce diverse protein isoforms from a single gene.

Pathways

U2AF35 is critically involved in the mRNA splicing pathway and the regulation of alternative splicing events. U2AF35 partners with another subunit U2AF65 in the spliceosome to facilitate these processes. It actively connects with several other proteins within the spliceosome machinery including SF3b and SF3a complexes. The interaction between U2AF35 and these elements ensures the correct assembly of the spliceosome directly influencing the pathway governing pre-mRNA processing.

Mutations in the U2AF35 gene can result in specific types of cancer such as myelodysplastic syndromes (MDS) where abnormal splicing patterns occur. Such mutations often affect the interaction of U2AF35 with other splicing factors like SF3B1. Additionally alterations in U2AF35 have associations with lung adenocarcinoma where changes in the mRNA splicing landscape empower cancer progression and malignancy. Understanding its role in splicing provides insight into how disruptions can lead to disease development.

Specifications

Form

Liquid

General info

Function

Plays a critical role in both constitutive and enhancer-dependent splicing by mediating protein-protein interactions and protein-RNA interactions required for accurate 3'-splice site selection. Recruits U2 snRNP to the branch point. Directly mediates interactions between U2AF2 and proteins bound to the enhancers and thus may function as a bridge between U2AF2 and the enhancer complex to recruit it to the adjacent intron.

Sequence similarities

Belongs to the splicing factor SR family.

Subcellular localisation

Nucleus

Product protocols

Target data

Plays a critical role in both constitutive and enhancer-dependent splicing by mediating protein-protein interactions and protein-RNA interactions required for accurate 3'-splice site selection. Recruits U2 snRNP to the branch point. Directly mediates interactions between U2AF2 and proteins bound to the enhancers and thus may function as a bridge between U2AF2 and the enhancer complex to recruit it to the adjacent intron.
See full target information U2AF1

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com